Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13143598 | 0.87 | CYP2A6 (0.55) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL24614167 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL9347774 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL9347724 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL1687607 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL368353 | 0.80 | CYP2A6 (0.55) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL2091527 | 0.79 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL9587702 | 0.79 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL7345698 | 0.78 | CYP2A6 (0.56) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL346786 | 0.78 | CYP2A6 (0.56) | CYP2A6ADRB2ASIC3LOXL2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190868-A1 | SUBSTITUTED BENZOCHALCOGENOACENE COMPOUND, THIN FILM COMPRISING THE COMPOUND, AND ORGANIC SEMICONDUCTOR DEVICE INCLUDING THE THIN FILM | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190868-A1 | SUBSTITUTED BENZOCHALCOGENOACENE COMPOUND, THIN FILM COMPRISING THE COMPOUND, AND ORGANIC SEMICONDUCTOR DEVICE INCLUDING THE THIN FILM | EBPL, SAAL1, APOL1 | CYP2A6 829/4885ADRB2 3433/4885ASIC3 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.